| Bemiparin | venous thrombosis, in all type of patients | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.78 [0.18 3.31] | p=1.00 | 0 | 324 | 1 | Kakkar, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar, 2003 | LMWH, 115 IU/kg qd followed by Bemiparin 3,500 IU qd | A: UFH, 30/40,000IU qd; B: LMWH, 115 IU/kg qd followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Ardeparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Levine, 1996 | ardeparin 50/kgx2 +elastic stockings | Placebo+elastic stockings | Knee |
| |
| Ardeparin | thrombosis prevention, in general surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.52 [0.03 8.33] | p=1.00 | 0 | 904 | 1 | Godwin, | | asymptomatic DVT | 0.07 [0.00 1.44] | p=1.00 | 0 | 904 | 1 | Godwin, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | no data | | Bleeding | 1.38 [0.82 2.33] | p=1.00 | 0 | 904 | 1 | Godwin, | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Godwin, 1993 | Ardeparin 90 and 50 units/kg b.i.d | UFH 10 000 units | Abdominopelvic surgery |
| |
| Certoparin | thrombosis prevention, in orthopedic surgery | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Haas , 1987 | Sandoz +0.5mg DHE | Unfractionated heparin | Elective hip | | Lassen, 1988 | certoparin 3000+0.5mg DHE, x1 | Placebo | Elective hip | | Lassen, 1989 | certoparin 3000+0.5mg DHE x1 | placebo | Hip fracture |
| |
| Certoparin | thrombosis prevention, in general surgery | vs unfractionated heparin | Bleeding by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.97 [0.56 1.68] | p=1.00 | 0 | 24801 | 5 | Schielke, Koppenhagen, Hoffmann and Largiader, Heilmann, Haas, | | asymptomatic DVT | 0.86 [0.63 1.17] | p=1.00 | 0 | 2921 | 11 | Schmitz-Huebner, Sasahara, Voigt, Welzel, Kakkar, Adolf, Heilmann, Baumgartner, Koppenhagen, Koppenhagen, Heilmann, | | Symptomatic venous thromboembolism (DVT, PE) | 0.27 [0.02 3.03] | p=1.00 | 0 | 326 | 2 | Schmitz-Huebner, Voigt, | | wound haematoma / infection | 2.79 [0.25 30.92] | p=1.00 | 0 | 777 | 2 | Koppenhagen, Koppenhagen, | | transfusion | 0.98 [0.72 1.33] | p=1.00 | 0 | 879 | 3 | Sasahara, Voigt, Adolf, | | All cause death | 1.07 [0.86 1.32] | p=1.00 | 0 | 24981 | 8 | Sasahara, Voigt, Baumgartner, Koppenhagen, Schielke, Koppenhagen, Heilmann, Haas, | | Bleeding | 0.58 [0.39 0.87] | p=0.04 | 0 | 737 | 3 | Voigt, Kakkar, Heilmann, | | Major bleeding | 0.84 [0.58 1.23] | p=1.00 | 0 | 3076 | 10 | Schmitz-Huebner, Voigt, Kakkar, Heilmann, Baumgartner, Hoffmann and Largiade, Koppenhagen, Schielke, Hoffmann and Largiader, Heilmann, |
| Trial | Studied treatment | Control | Patients |
|---|
| Schmitz-Huebner, 1984 | Certoparin (dose 1 and dose 2) b.i.d. | UFH 10 000 units | Abdominal surgery | | Sasahara, 1986 | Certoparin 3000 + DHE | UFH 10 000 units +DHE | Abdominal surgery | | Voigt, 1986 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Welzel, 1988 | Certoparin 2500 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Kakkar, 1989 | Certoparin 3000 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Adolf, 1989 | Certoparin 3000 | UFH 15 000 units | Abdominal surgery | | Heilmann, 1989 | Certoparin 3000 | UFH 15 000 units | Gynaecological surgery | | Baumgartner, 1989 | Certoparin 3000 + DHE | UFH 5 000 units+DHE | Abdominal surgery | | Hoffmann and Largiade, 1990 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Koppenhagen, 1990 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery | | Schielke, 1991 | Certoparin 3000 anti Xa units + DHE | UFH 10 000 units + DHE | Abdominal surgery | | Koppenhagen, 1992 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery | | Hoffmann and Largiader, 1992 | Certoparin 3000 anti Xa units | UFH 10 000 units | Abdominothoracic surgery | | Heilmann, 1997 | Certoparin 3000 anti Xa units | UFH 15 000 units | Gynaecological and breast surgery | | Haas, 1999 | Certoparin 3000 anti Xa units | UFH 15 000 units | General surgery |
| |
| Certoparin | thrombosis prevention, in abdominal surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.30 [0.03 3.19] | p=1.00 | 0 | 771 | 2 | Schielke, Koppenhagen, | | asymptomatic DVT | 0.88 [0.63 1.22] | p=1.00 | 0 | 2297 | 9 | Schmitz-Huebner, Sasahara, Voigt, Welzel, Kakkar, Adolf, Baumgartner, Koppenhagen, Koppenhagen, | | Symptomatic venous thromboembolism (DVT, PE) | 0.27 [0.02 3.03] | p=1.00 | 0 | 326 | 2 | Schmitz-Huebner, Voigt, | | wound haematoma / infection | 2.79 [0.25 30.92] | p=1.00 | 0 | 777 | 2 | Koppenhagen, Koppenhagen, | | transfusion | 0.98 [0.72 1.33] | p=1.00 | 0 | 879 | 3 | Sasahara, Voigt, Adolf, | | All cause death | 0.56 [0.26 1.22] | p=1.00 | 0 | 1545 | 6 | Sasahara, Voigt, Baumgartner, Koppenhagen, Schielke, Koppenhagen, | | Bleeding | 0.83 [0.36 1.93] | p=1.00 | 0 | 379 | 2 | Voigt, Kakkar, | | Major bleeding | 1.29 [0.65 2.55] | p=1.00 | 0 | 1824 | 7 | Schmitz-Huebner, Voigt, Kakkar, Baumgartner, Hoffmann and Largiade, Koppenhagen, Schielke, |
| Trial | Studied treatment | Control | Patients |
|---|
| Schmitz-Huebner, 1984 | Certoparin (dose 1 and dose 2) b.i.d. | UFH 10 000 units | Abdominal surgery | | Sasahara, 1986 | Certoparin 3000 + DHE | UFH 10 000 units +DHE | Abdominal surgery | | Voigt, 1986 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Welzel, 1988 | Certoparin 2500 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Kakkar, 1989 | Certoparin 3000 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Adolf, 1989 | Certoparin 3000 | UFH 15 000 units | Abdominal surgery | | Baumgartner, 1989 | Certoparin 3000 + DHE | UFH 5 000 units+DHE | Abdominal surgery | | Hoffmann and Largiade, 1990 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Koppenhagen, 1990 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery | | Schielke, 1991 | Certoparin 3000 anti Xa units + DHE | UFH 10 000 units + DHE | Abdominal surgery | | Koppenhagen, 1992 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery |
| |
| Certoparin | thrombosis prevention, in gynaecological surgery | vs unfractionated heparin | Bleeding by 48% suggested Major bleeding by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.75 [0.50 6.09] | p=1.00 | 0 | 358 | 1 | Heilmann, | | asymptomatic DVT | 0.78 [0.36 1.73] | p=1.00 | 0 | 624 | 2 | Heilmann, Heilmann, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | 1.67 [0.39 7.08] | p=1.00 | 0 | 358 | 1 | Heilmann, | | Bleeding | 0.52 [0.33 0.83] | p=0.04 | 0 | 358 | 1 | Heilmann, | | Major bleeding | 0.58 [0.35 0.96] | p=0.04 | 0 | 658 | 2 | Heilmann, Heilmann, |
| Trial | Studied treatment | Control | Patients |
|---|
| Heilmann, 1989 | Certoparin 3000 | UFH 15 000 units | Gynaecological surgery | | Heilmann, 1997 | Certoparin 3000 anti Xa units | UFH 15 000 units | Gynaecological and breast surgery |
| |
| Certoparin | thrombosis prevention, in medical patients | vs UFH | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | no data | | Symptomatic pulmonary embolism | no data | | Deep vein thrombosis | no data | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | no data | | pulmonary embolism (symptomatic and asymptomatic) | no data | | fatal pulmonary embolism | no data | | Venous thromboembolism | no data | | All cause death | no data | | Major bleeding | no data | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CERTIFY, 2010 | | | |
| |
| Dalteparin | thrombosis prevention, in general surgery | vs placebo | asymptomatic DVT by 74% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.19 [0.01 3.93] | p=1.00 | 0 | 197 | 1 | Ockelford , | | asymptomatic DVT | 0.26 [0.08 0.84] | p=0.04 | 0 | 183 | 1 | Ockelford , | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 4.66 [0.22 98.28] | p=1.00 | 0 | 197 | 1 | Ockelford , | | transfusion | no data | | Bleeding | 2.33 [0.70 7.69] | p=1.00 | 0 | 197 | 1 | Ockelford , | | Major bleeding | 0.93 [0.23 3.83] | p=1.00 | 0 | 197 | 1 | Ockelford , | | All cause death | 0.19 [0.01 3.93] | p=1.00 | 0 | 197 | 1 | Ockelford , |
| Trial | Studied treatment | Control | Patients |
|---|
| Ockelford , 1989 | Dalteparin 2500 anti-Xa units | Placebo | general surgery |
| |
| Dalteparin | | vs unfractionated heparin | wound haematoma / infection by 49% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.21 [0.66 2.22] | p=1.00 | 0 | 3961 | 2 | Borstad, Kakkar, | | asymptomatic DVT | 0.90 [0.63 1.29] | p=1.00 | 0 | 2764 | 10 | Bergqvist, Onarheim, Koller, Fricker, Bergqvist, Caen, Borstad, Briel, Creperio, Hartl, | | Symptomatic venous thromboembolism (DVT, PE) | 0.37 [0.07 2.10] | p=1.00 | 0 | 335 | 3 | Fricker, Borstad, Creperio, | | wound haematoma / infection | 0.51 [0.33 0.79] | p=0.04 | 0 | 3961 | 2 | Borstad, Kakkar, | | transfusion | 1.09 [0.89 1.33] | p=1.00 | 0 | 2262 | 6 | Bergqvist, Koller, Koller, Bergqvist, Caen, Hartl, | | All cause death | 1.26 [0.93 1.72] | p=1.00 | 0 | 5843 | 8 | Onarheim, Koller, Koller, Bergqvist, Caen, Hartl, Borstad, Kakkar, | | Bleeding | 0.94 [0.80 1.11] | p=1.00 | 0 | 6570 | 11 | Bergqvist, Onarheim, Koller, Koller, Fricker, Bergqvist, Caen, Borstad, Hartl, Borstad, Kakkar, | | Major bleeding | 0.92 [0.70 1.22] | p=1.00 | 0 | 5568 | 10 | Bergqvist, Onarheim, Koller, Koller, Fricker, Caen, Borstad, Hartl, Borstad, Kakkar, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergqvist, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Onarheim, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 7500 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Fricker, 1988 | Dalteparin 5000 | UFH 15 000 units | Abdominopelvic surgery | | Bergqvist, 1988 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Caen, 1988 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Borstad, 1988 | Dalteparin 5000 | UFH 10 000 units | Gynaecological surgery | | Briel, 1988 | Dalteparin 5000 | UFH 10 000 units+DHE | Gynaecological surgery | | Creperio, 1990 | Dalteparin 2500 | UFH 10 000 units | General surgery | | Hartl, 1990 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Borstad, 1992 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Gynaecological surgery | | Kakkar, 1993 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery |
| |
| Dalteparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Jorgensen, 1989 | dalteparin 5000 x1 | Placebo | Hip fracture | | Torholm, 1991 | dalteparin 5000x1 | Placebo | Elective hip |
| |
| Dalteparin | | vs Dextran | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Eriksson , 1988 | dalteparin | Dextran | Elective hip | | Matzsch , 1988 | dalteparin | Dextran | Elective hip | | Matzsch , 1991 | dalteparin | Dextran | Elective hip |
| |
| Dalteparin | | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Haas , 1985 | dalteparin | Unfractionated heparin | Elective hip | | Binsack , 1986 | dalteparin | Unfractionated heparin | Elective hip | | Barre , 1987 | dalteparin | Unfractionated heparin | Elective hip | | Dechavanne , 1989 | dalteparin | Unfractionated heparin | Elective hip | | Eriksson , 1989 | dalteparin | Unfractionated heparin | Elective hip | | Monreal , 1989 | dalteparin | Unfractionated heparin | Hip |
| |
| Dalteparin | thrombosis prevention, in medical patients | vs placebo | Deep vein thrombosis by 51% suggested asymptomatic DVT by 49% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | 0.45 [0.16 1.31] | p=1.00 | 0 | 3706 | 1 | Leizorovicz, | | Symptomatic pulmonary embolism | 0.83 [0.25 2.73] | p=1.00 | 0 | 3706 | 1 | Leizorovicz, | | Deep vein thrombosis | 0.49 [0.32 0.75] | p=0.04 | 0 | 3706 | 1 | Leizorovicz, | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | 0.51 [0.32 0.81] | p=0.04 | 0 | 3706 | 1 | Leizorovicz, | | pulmonary embolism (symptomatic and asymptomatic) | 0.83 [0.25 2.73] | p=1.00 | 0 | 3499 | 1 | Leizorovicz, | | fatal pulmonary embolism | 0.20 [0.01 4.12] | p=1.00 | 0 | 3636 | 1 | Leizorovicz, | | Venous thromboembolism | no data | | All cause death | 1.02 [0.66 1.57] | p=1.00 | 0 | 3706 | 1 | Leizorovicz, | | Major bleeding | 16.95 [0.98 293.81] | p=1.00 | 0 | 3706 | 1 | Leizorovicz, | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Leizorovicz, 2004 | Dalteparin 5000E once daily, 1 days | placebo | Congestive heart failure (NYHA III–IV), acute or chronic respiratory disease, infectious and rheumatologic disease |
| |
| Dalteparin | | vs UFH | pulmonary embolism (symptomatic and asymptomatic) by 44% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | no data | | Symptomatic pulmonary embolism | no data | | Deep vein thrombosis | 0.86 [0.68 1.09] | p=1.00 | 0 | 3746 | 1 | PROTECT, | | proximal deep-vein thrombosis | 0.88 [0.66 1.17] | p=1.00 | 0 | 3746 | 1 | PROTECT, | | Venous thromboembolism or death | 0.90 [0.78 1.04] | p=1.00 | 0 | 3746 | 1 | PROTECT, | | asymptomatic DVT | no data | | pulmonary embolism (symptomatic and asymptomatic) | 0.56 [0.34 0.92] | p=0.04 | 0 | 3746 | 1 | PROTECT, | | fatal pulmonary embolism | no data | | Venous thromboembolism | no data | | All cause death | 0.90 [0.78 1.05] | p=1.00 | 0 | 3746 | 1 | PROTECT, | | Major bleeding | 0.98 [0.74 1.30] | p=1.00 | 0 | 3746 | 1 | PROTECT, | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PROTECT, 2011 | subcutaneous dalteparin 5000 IU once daily | unfractionated heparin 5000 IU twice daily | critically ill patients |
| |
| Dalteparin | thrombosis prevention, in abdominal surgery | vs unfractionated heparin | wound haematoma / infection by 48% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.17 [0.63 2.17] | p=1.00 | 0 | 3809 | 1 | Kakkar, | | asymptomatic DVT | 0.87 [0.60 1.26] | p=1.00 | 0 | 2316 | 7 | Bergqvist, Onarheim, Koller, Fricker, Bergqvist, Caen, Hartl, | | Symptomatic venous thromboembolism (DVT, PE) | 0.20 [0.02 1.80] | p=1.00 | 0 | 80 | 1 | Fricker, | | wound haematoma / infection | 0.52 [0.33 0.84] | p=0.04 | 0 | 3809 | 1 | Kakkar, | | transfusion | 1.09 [0.89 1.33] | p=1.00 | 0 | 2262 | 6 | Bergqvist, Koller, Koller, Bergqvist, Caen, Hartl, | | All cause death | 1.25 [0.91 1.70] | p=1.00 | 0 | 5691 | 7 | Onarheim, Koller, Koller, Bergqvist, Caen, Hartl, Kakkar, | | Bleeding | 0.91 [0.76 1.09] | p=1.00 | 0 | 6203 | 9 | Bergqvist, Onarheim, Koller, Koller, Fricker, Bergqvist, Caen, Hartl, Kakkar, | | Major bleeding | 0.87 [0.65 1.17] | p=1.00 | 0 | 5201 | 8 | Bergqvist, Onarheim, Koller, Koller, Fricker, Caen, Hartl, Kakkar, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergqvist, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Onarheim, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 7500 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Fricker, 1988 | Dalteparin 5000 | UFH 15 000 units | Abdominopelvic surgery | | Bergqvist, 1988 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Caen, 1988 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Hartl, 1990 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Kakkar, 1993 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery |
| |
| Dalteparin | thrombosis prevention, in gynaecological surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 2.92 [0.12 72.89] | p=1.00 | 0 | 152 | 1 | Borstad, | | asymptomatic DVT | 1.04 [0.11 10.07] | p=1.00 | 0 | 408 | 2 | Borstad, Briel, | | Symptomatic venous thromboembolism (DVT, PE) | 1.05 [0.02 53.29] | p=1.00 | 0 | 215 | 1 | Borstad, | | wound haematoma / infection | 0.44 [0.15 1.34] | p=1.00 | 0 | 152 | 1 | Borstad, | | transfusion | no data | | All cause death | 4.87 [0.23 103.18] | p=1.00 | 0 | 152 | 1 | Borstad, | | Bleeding | 1.12 [0.73 1.71] | p=1.00 | 0 | 367 | 2 | Borstad, Borstad, | | Major bleeding | 1.46 [0.62 3.46] | p=1.00 | 0 | 367 | 2 | Borstad, Borstad, |
| Trial | Studied treatment | Control | Patients |
|---|
| Borstad, 1988 | Dalteparin 5000 | UFH 10 000 units | Gynaecological surgery | | Briel, 1988 | Dalteparin 5000 | UFH 10 000 units+DHE | Gynaecological surgery | | Borstad, 1992 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Gynaecological surgery |
| |
| Dalteparin | venous thrombosis, in all type of patients | vs warfarin | VTE during active anticoagulant treatment by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.58 [0.36 0.93] | p=0.04 | 0 | 777 | 2 | Das, Lee, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Das, 1996 | UFH followed by Dalteparin 5,000 IU qd | UFH followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Lee, 2003 | LMWH, 200 IU/kg qd followed by Dalteparin 150 IU/kg qd | LMWH, 200 IU/kg qd followed by Warfarin target INR 2-3 | patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Dalteparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.21 [0.49 2.97] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | Thrombus extension | 0.59 [0.25 1.43] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | All cause death | 1.38 [0.57 3.30] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | Short term haemorrhage | 1.17 [0.21 6.42] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Bratt et al , 1985 | Dalteparin Intravenousv (ajusted) for >=5 Days, 120 U/kg BID | unfractionated heparin intravenous APPTx1.7-3.5 | | | Holm et al , 1986 | Dalteparin Subcutaneous twice daily ajusted for 7 Days, 57-107 U/kg BID | unfractionated heparin subcutaneous twice daily 16000-30000 U | | | Bratt et al, 1990 | Dalteparin Subcutaneous twice daily ajusted for >= 5 Days, 120 U/kg BID | unfractionated heparin intravenous APPTx2-4 | | | Lindmarker et al , 1993 | Dalteparin Subcutaneous once daily for >= 5 Days, 200 U/kg BID | unfractionated heparin intravenous APPTx1.5-3 | |
| |
| Dalteparin | | vs twice daily dalteparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | All cause death | 2.53 [0.26 24.90] | p=1.00 | 0 | 140 | 1 | Partsch, | | Bleeding | 0.95 [0.10 9.31] | p=1.00 | 0 | 227 | 2 | Holmström, Partsch, |
| Trial | Studied treatment | Control | Patients |
|---|
| Holmström, 1992 | once daily dalteparin 200 U (anti-FXa)/kg for at least 5 days | twice daily dalteparin 100
U (anti-FXa)/kg for at least 5 days | Patients with a first occurence of DVT in the lower limb, confirmed with phlebographytio | | Partsch, 1996 | Fragmin administered 200 IU/kg once daily for at least 7 days | Fragmin 100 IU/kg twice daily for at least 7 days | patients presented with DVT extending into the iliofemoral segment diagnosed by duplex ultrasonographyA |
| |
| Enoxaparin | thrombosis prevention, in orthopedic surgery | vs no treatment | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Warwick, 1995 | enoxaparin 4000x1 + elastic stockings | no treatment + elastic stockings | Elective hip |
| |
| Enoxaparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Turpie, 1986 | Enoxaparin 3000 x2 | Placebo | Elective hip | | Leclerc, 1991 | Enoxaparin 3000 x2 | Placebo | Knee | | Samama, 1997 | enoxaparin 4000x1+elastic stockings | Placebo+elastic stockings | Elective hip | | Kalodiki, 1996 | enoxaparin 4000x1 | Placebo | Elective hip |
| |
| Enoxaparin | | vs Dextran | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| DES Group , 1991 | Enoxaparin | Dextran | Elective hip |
| |
| Enoxaparin | | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Planes , 1988 | Enoxaparin | Unfractionated heparin | Elective hip | | Levine , 1991 | Enoxaparin | Unfractionated heparin | Elective hip |
| |
| Enoxaparin | thrombosis prevention, in medical patients | vs placebo | asymptomatic DVT by 61% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | 0.60 [0.21 1.68] | p=1.00 | 0 | 859 | 2 | MEDENOX, Lederle, | | Symptomatic pulmonary embolism | 0.24 [0.04 1.48] | p=1.00 | 0 | 859 | 2 | MEDENOX, Lederle, | | Deep vein thrombosis | 0.72 [0.49 1.05] | p=1.00 | 0 | 579 | 1 | MEDENOX, | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | 0.39 [0.21 0.71] | p=0.04 | 0 | 579 | 1 | MEDENOX, | | pulmonary embolism (symptomatic and asymptomatic) | 0.23 [0.05 1.14] | p=1.00 | 0 | 859 | 2 | MEDENOX, Lederle, | | fatal pulmonary embolism | no data | | Venous thromboembolism | no data | | All cause death | 0.98 [0.81 1.19] | p=1.00 | 0 | 8886 | 2 | MEDENOX, LIFENOX, | | Major bleeding | 1.20 [0.66 2.19] | p=1.00 | 0 | 9166 | 3 | MEDENOX, Lederle, LIFENOX, | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| MEDENOX, 1999 | Enoxaparin 20 mg or 40 mg once daily, 6–14 days | placebo | Acute decompensated chronic obstructive pulmonary disease with mechanical ventilation | | Lederle, 2006 | Enoxaparin 40 mg once daily, until hospital discharge | placebo | Hospitalization in general medical unit | | LIFENOX, 2011 | subcutaneous enoxaparin 40 mg daily for 10±4 days | placebo | hospitalized, acutely ill medical patients |
| |
| Enoxaparin | | vs UFH | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | no data | | Symptomatic pulmonary embolism | no data | | Deep vein thrombosis | 0.77 [0.48 1.24] | p=1.00 | 0 | -54 | 3 | Bergmann and Neuhart, Lechler, Kleber, | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | no data | | pulmonary embolism (symptomatic and asymptomatic) | no data | | fatal pulmonary embolism | no data | | Venous thromboembolism | no data | | All cause death | 0.68 [0.41 1.15] | p=1.00 | 0 | -54 | 3 | Bergmann and Neuhart, Lechler, Kleber, | | Major bleeding | no data | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergmann and Neuhart, 1996 | enoxaparin 20 mg once daily for 10 days | unfractionated heparin (UFH) 5000 IU twice daily | elderly in-patients bedridden for an acute medical illness | | Lechler, 1996 | enoxaparin 40 mg | unfractionated heparin (Ca-heparin), 3 x 5,000 U) | hospitalized medical patients | | Kleber, 2003 | enoxaparin 40 mg once daily for 10 +/2 days | UFH 5000 IU 3 times daily for 10 +/2 days | severe respiratory disease or heart failure |
| |
| Enoxaparin | thrombosis prevention, in general surgery | vs no treatment | Bleeding by 278% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.18 [0.01 3.52] | p=1.00 | 0 | 303 | 1 | Ho [43], | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | 0.11 [0.01 2.09] | p=1.00 | 0 | 303 | 1 | Ho [43], | | wound haematoma / infection | 6.31 [0.30 132.48] | p=1.00 | 0 | 303 | 1 | Ho [43], | | transfusion | 1.43 [0.77 2.68] | p=1.00 | 0 | 303 | 1 | Ho [43], | | Bleeding | 3.78 [1.00 14.26] | p=0.04 | 0 | 303 | 1 | Ho [43], | | Major bleeding | 3.78 [0.39 36.80] | p=1.00 | 0 | 303 | 1 | Ho [43], | | All cause death | 1.89 [0.31 11.49] | p=1.00 | 0 | 303 | 1 | Ho [43], |
| Trial | Studied treatment | Control | Patients |
|---|
| Ho [43], | Enoxaparin 4000 anti-Xa units | No treatment | |
| |
| Enoxaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.68 [0.22 2.06] | p=1.00 | 0 | 3942 | 5 | Kaaja, Gazzaniga (ISG), Nurmohamed, Gonzalez, ENOXACAN, | | asymptomatic DVT | 0.97 [0.76 1.24] | p=1.00 | 0 | 5085 | 8 | Samama 1, Samama 2, Samama 3, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, | | Symptomatic venous thromboembolism (DVT, PE) | 0.58 [0.11 2.96] | p=1.00 | 0 | 892 | 3 | Samama 1, Samama 2, Samama 3, | | wound haematoma / infection | 0.66 [0.24 1.79] | p=1.00 | 0 | 68 | 1 | Kaaja, | | transfusion | 1.08 [0.83 1.41] | p=1.00 | 0 | 892 | 3 | Samama 1, Samama 2, Samama 3, | | All cause death | 0.75 [0.49 1.17] | p=1.00 | 0 | 4766 | 7 | Samama 1, Samama 2, Samama 3, Gazzaniga (ISG), Nurmohamed, Gonzalez, ENOXACAN, | | Bleeding | 0.94 [0.80 1.10] | p=1.00 | 0 | 6183 | 9 | Samama 1, Samama 2, Samama 3, Kaaja, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, | | Major bleeding | 1.03 [0.72 1.47] | p=1.00 | 0 | 6183 | 9 | Samama 1, Samama 2, Samama 3, Kaaja, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, |
| Trial | Studied treatment | Control | Patients |
|---|
| Samama 1, 1988 | Enoxaparin 2000 | UFH 15 000 units | General surgery | | Samama 2, 1988 | Enoxaparin 4000 | UFH 15 000 units | General surgery | | Samama 3, 1988 | Enoxaparin 6000 | UFH 15 000 units | General surgery | | Kaaja, 1992 | Enoxaparin 2000 anti Xa units | UFH 10 000 units | Gynaecological surgery | | Gazzaniga (ISG), 1993 | Enoxaparin 2000 anti Xa units | UFH 10 000 units | General and vascular surgery | | Nurmohamed, 1995 | Enoxaparin 2000 anti Xa units | UFH 15 000 units | General surgery | | McLeod (Canadian), 1995 | Enoxaparin 4000 anti Xa units | UFH 15 000 units | Colorectal surgery | | Gonzalez, 1996 | Bemiparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery | | ENOXACAN, 1997 | Enoxaparin 4000 anti Xa units | UFH 15 000 units | Abdominopelvic surgery |
| |
| Enoxaparin | thrombosis prevention, in gynaecological surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.84 [0.02 43.49] | p=1.00 | 0 | 68 | 1 | Kaaja, | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 0.66 [0.24 1.79] | p=1.00 | 0 | 68 | 1 | Kaaja, | | transfusion | no data | | All cause death | no data | | Bleeding | 0.46 [0.17 1.28] | p=1.00 | 0 | 68 | 1 | Kaaja, | | Major bleeding | 0.06 [0.00 1.20] | p=1.00 | 0 | 68 | 1 | Kaaja, |
| Trial | Studied treatment | Control | Patients |
|---|
| Kaaja, 1992 | Enoxaparin 2000 anti Xa units | UFH 10 000 units | Gynaecological surgery |
| |
| Enoxaparin | thrombosis prevention, in abdominal surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.98 [0.02 49.79] | p=1.00 | 0 | 166 | 1 | Gonzalez, | | asymptomatic DVT | 1.00 [0.65 1.55] | p=1.00 | 0 | 1102 | 2 | McLeod (Canadian), Gonzalez, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | 0.98 [0.02 49.79] | p=1.00 | 0 | 166 | 1 | Gonzalez, | | Bleeding | 1.26 [0.87 1.82] | p=1.00 | 0 | 1515 | 2 | McLeod (Canadian), Gonzalez, | | Major bleeding | 1.21 [0.69 2.12] | p=1.00 | 0 | 1515 | 2 | McLeod (Canadian), Gonzalez, |
| Trial | Studied treatment | Control | Patients |
|---|
| McLeod (Canadian), 1995 | Enoxaparin 4000 anti Xa units | UFH 15 000 units | Colorectal surgery | | Gonzalez, 1996 | Bemiparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery |
| |
| Enoxaparin | thrombosis prevention, in neurosurgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 1.00 [0.27 3.75] | p=1.00 | 0 | 437 | 2 | Agnelli, Melon, | | Major bleeding | 1.00 [0.27 3.75] | p=1.00 | 0 | 437 | 2 | Agnelli, Melon, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Agnelli, 1998 | Enoxaparin, 40 mg/d subcutaneously within 24 hours postoperatively plus compression stockings for >=7 days | compression stockings + placebo | Elective neurosurgery, 18 years or older, without excess bleeding risk | | Melon, 1987 | Enoxaparin, 20 mg/d subcutaneously 18-24 hours postoperatively for 10 days | placebo | Neurosurgery, adult, 45-90 kg of weight, without excess bleeding risk |
| |
| Enoxaparin | venous thrombosis, in all type of patients | vs acenocoumarol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Veiga, | | VTE during follow-up after active anticoagulant treatment | 1.25 [0.35 4.41] | p=1.00 | 0 | 96 | 1 | Veiga, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Veiga, 2000 | UFH, APTT 1.5–2.0d followed by Enoxaparin 4,000 IU qd | UFH, APTT 1.5–2.0d followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by Venography |
| |
| Enoxaparin | | vs coumarin | VTE during active anticoagulant treatment by 97% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 1.97 [1.06 3.66] | p=0.04 | 0 | 165 | 1 | González-Fajardo, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| González-Fajardo, 2008 | long-term anticoagulant treatment with enoxaparin during at least 3 months | long-term anticoagulant treatment with coumarin during at least 3 months | patients with symptomatic, unilateral, first-episode DVT |
| |
| Enoxaparin | | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.62 [0.31 1.24] | p=1.00 | 0 | 453 | 3 | Pini, Gonzalez-Fajardo, Deitcher, | | VTE during follow-up after active anticoagulant treatment | 2.91 [0.96 8.85] | p=1.00 | 0 | 299 | 2 | Pini, Meyer, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Pini, 1994 | UFH, APTT 1.3–1.9 followed by Enoxaparin 4,000 IU qd | UFH, APTT 1.3–1.9 followed by Warfarin target INR 2-3.5 | patients with objective diagnosis of DVT by Venography (diagnosed by strain-gauge plethysmography plus D-dimer latex assay and confirmed by venography) | | Gonzalez-Fajardo, 1999 | LMWH, 4,000 IU bid followed by Enoxaparin 4,000 IU qd | UFH followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Meyer, 2002 | LMWH, 1.5 mg/kg qd followed by Enoxaparin 1.5 mg/Kg qd | LMWH, 1.5 mg/kg qd followed by Warfarin target INR 2-3 | patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography | | Deitcher, 2003 | LMWH: 1a, 1 mg/kg q12h; 1b, 1 mg/kg qd12h followed by Enoxaparin 1a: 1 mg/kg qd; 1b: 1.5 mg/kg qd | LMWH, 1 mg/kg q12h followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT |
| |
| Enoxaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.14 [0.01 2.82] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | Thrombus extension | 0.14 [0.02 1.20] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | All cause death | 1.50 [0.24 9.28] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | Short term haemorrhage | 1.00 [0.02 51.15] | p=1.00 | 0 | 134 | 1 | Simonneau et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Simonneau et al , 1993 | Enoxaparin Subcutaneous twice daily for 0 Days, 100 U/kg BID | unfractionated heparin intravenous APPTx1.5-2.5 | |
| |
| Enoxaparin | | vs twice daily enoxaparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.51 [0.64 3.59] | p=1.00 | 0 | 610 | 1 | Merli, | | All cause death | 1.65 [0.63 4.30] | p=1.00 | 0 | 610 | 1 | Merli, | | Bleeding | 1.31 [0.35 4.92] | p=1.00 | 0 | 610 | 1 | Merli, |
| Trial | Studied treatment | Control | Patients |
|---|
| Merli, 2001 | enoxaparin 1.5 mg/kg body weight
once daily | S.c. enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily | patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE) |
| |
| Enoxaparin | | vs UFH | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.05 [0.47 2.35] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), | | All cause death | 1.19 [0.49 2.91] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), | | Bleeding | 1.15 [0.72 1.82] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), |
| Trial | Studied treatment | Control | Patients |
|---|
| Merli (once daily vs UFH), 2001 | Initial therapy with enoxaparin 1.5 mg/kg body weight
once daily
| Initial therapy with dose-adjusted intravenous
unfractionated heparin | patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)
|
| |
| Fraxiparin | thrombosis prevention, in general surgery | vs placebo | Major bleeding by 151% adverse event Symptomatic venous thromboembolism (DVT, PE) by 71% suggested wound haematoma / infection by 88% suggested transfusion by 65% suggested Bleeding by 109% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.25 [0.05 1.18] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | 0.29 [0.11 0.80] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | wound haematoma / infection | 1.88 [1.52 2.33] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | transfusion | 1.65 [1.32 2.07] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Bleeding | 2.09 [1.76 2.50] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Major bleeding | 2.51 [1.89 3.34] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | All cause death | 0.45 [0.19 1.03] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, |
| Trial | Studied treatment | Control | Patients |
|---|
| Pezzuoli, 1989 | Nadroparin 2850 anti-Xa units | Placebo | general surgery |
| |
| Fraxiparin | thrombosis prevention, in orthopedic surgery | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Leyvraz, 1991 | Fraxiparin | Unfractionated heparin | Elective hip |
| |
| LMWH | thrombosis prevention, in medical patients | vs UFH | All cause death by 150% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | no data | | Symptomatic pulmonary embolism | no data | | Deep vein thrombosis | 1.07 [0.31 3.66] | p=1.00 | 0 | -36 | 2 | Harenberg, Harenberg, | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | no data | | pulmonary embolism (symptomatic and asymptomatic) | no data | | fatal pulmonary embolism | no data | | Venous thromboembolism | no data | | All cause death | 2.50 [1.22 5.15] | p=0.04 | 0 | -36 | 2 | Harenberg, Harenberg, | | Major bleeding | no data | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Harenberg, 1990 | 1 x 1.500 aPTT units of a LMW heparin fraction | 3 x 5.000 IU of an unfractionated heparin | patients aged 40-80 years | | Harenberg, 1996 | 1 daily subcutaneous administration of LMW heparin for 10 days | 3 x 5,000 IU unfractionated (UF) heparin for 10 days | medical inpatients |
| |
| Nadroparin | thrombosis prevention, in orthopedic surgery | vs no treatment | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Yoo, 1997 | nadroparin 41/kgx1 days 1-3, 62/kg x1 days 4-11+elastic stockings | no treatment | Elective hip |
| |
| Nadroparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Sourmelis, 1995 | nadroparin 3075x1 preop, 6150x1 post op | Placebo | Hip fracture |
| |
| Nadroparin | thrombosis prevention, in medical patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic deep-vein thrombosis | 1.05 [0.02 53.18] | p=1.00 | 0 | 223 | 1 | Fraisse, | | Symptomatic pulmonary embolism | 0.61 [0.28 1.31] | p=1.00 | 0 | 2697 | 2 | Fraisse, Mahe, | | Deep vein thrombosis | 0.55 [0.30 1.00] | p=1.00 | 0 | 223 | 1 | Fraisse, | | proximal deep-vein thrombosis | no data | | Venous thromboembolism or death | no data | | asymptomatic DVT | 0.57 [0.27 1.18] | p=1.00 | 0 | 223 | 1 | Fraisse, | | pulmonary embolism (symptomatic and asymptomatic) | 0.59 [0.27 1.30] | p=1.00 | 0 | 2474 | 1 | Mahe, | | fatal pulmonary embolism | 0.59 [0.27 1.30] | p=1.00 | 0 | 2474 | 1 | Mahe, | | Venous thromboembolism | no data | | All cause death | 0.98 [0.83 1.16] | p=1.00 | 0 | 2679 | 3 | Fraisse, Mahe, Bergmann, | | Major bleeding | 1.26 [0.38 4.16] | p=1.00 | 0 | 2697 | 2 | Fraisse, Mahe, | | net benefit | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Fraisse, 2000 | Nadroparin 3800–5700E once daily, Until no longer mechanical ventilation, <=21 days | placebo | Acute decompensated chronic obstructive pulmonary diseasewith mechanical ventilation | | Mahe, 2005 | nadroparin 7500E once daily, Until hospital discharge, <=21 days | placebo | Congestive heart failure (NYHA III–IV), acute or respiratory disease, nonpulmonary sepsis, cancer | | Bergmann, 1996 | nadroparin 7500 u anti-Xa once daily | placebo | hospitalized medical |
| |
| Nadroparin | thrombosis prevention, in general surgery | vs no treatment | asymptomatic DVT by 81% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | 0.19 [0.04 0.94] | p=0.04 | 0 | 61 | 1 | Marassi [41], | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 0.35 [0.01 9.05] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | transfusion | 1.15 [0.42 3.10] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | Bleeding | 0.35 [0.01 9.05] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | Major bleeding | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Marassi [41], | Nadroparin 2850 anti-Xa units | No treatment | |
| |
| Nadroparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.34 [0.01 8.38] | p=1.00 | 0 | 189 | 1 | Balas [40], | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 0.58 [0.16 2.04] | p=1.00 | 0 | 189 | 1 | Balas [40], | | Major bleeding | 0.20 [0.01 4.27] | p=1.00 | 0 | 189 | 1 | Balas [40], | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Balas [40], | Nadroparin 2850 anti-Xa units | Placebo | |
| |
| Nadroparin | | vs unfractionated heparin | asymptomatic DVT by 39% suggested Symptomatic venous thromboembolism (DVT, PE) by 75% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.20 [0.01 4.25] | p=1.00 | 0 | 344 | 1 | Barbui, | | asymptomatic DVT | 0.61 [0.40 0.93] | p=0.04 | 0 | 2917 | 5 | Kakkar and Murray, EFS, Dahan, Barbui, Eurin, | | Symptomatic venous thromboembolism (DVT, PE) | 0.25 [0.08 0.83] | p=0.04 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | wound haematoma / infection | 1.12 [0.45 2.84] | p=1.00 | 0 | 344 | 1 | Barbui, | | transfusion | 1.04 [0.84 1.29] | p=1.00 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | All cause death | 0.87 [0.44 1.72] | p=1.00 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | Bleeding | 1.00 [0.81 1.24] | p=1.00 | 0 | 2389 | 2 | EFS, Eurin, | | Major bleeding | 2.98 [0.12 73.40] | p=1.00 | 0 | 480 | 1 | Eurin, |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar and Murray, 1985 | Nadroparin 2850 | UFH 10 000 units | General surgery | | EFS, 1988 | Nadroparin 2850 | UFH 15 000 units | Abdominal surgery | | Dahan, 1989 | Nadroparin 2850 | UFH 15 000 units | Thoracic surgery | | Barbui, 1990 | Nadroparin 2850 anti Xa units | UFH 10 000 units | General surgery | | Eurin, 1994 | Nadroparin 2850 anti Xa units | UFH 15 000 units | Abdominopelvic surgery |
| |
| Nadroparin | thrombosis prevention, in abdominal surgery | vs unfractionated heparin | Symptomatic venous thromboembolism (DVT, PE) by 73% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | 0.63 [0.38 1.03] | p=1.00 | 0 | 1896 | 1 | EFS, | | Symptomatic venous thromboembolism (DVT, PE) | 0.27 [0.07 0.95] | p=0.04 | 0 | 1909 | 1 | EFS, | | wound haematoma / infection | no data | | transfusion | 1.01 [0.79 1.30] | p=1.00 | 0 | 1909 | 1 | EFS, | | All cause death | 0.89 [0.39 2.03] | p=1.00 | 0 | 1909 | 1 | EFS, | | Bleeding | 0.99 [0.79 1.25] | p=1.00 | 0 | 1909 | 1 | EFS, | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EFS, 1988 | Nadroparin 2850 | UFH 15 000 units | Abdominal surgery |
| |
| Nadroparin | thrombosis prevention, in neurosurgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 3.04 [0.61 15.20] | p=1.00 | 0 | 485 | 1 | Nurmohamed, | | Major bleeding | 3.04 [0.61 15.20] | p=1.00 | 0 | 485 | 1 | Nurmohamed, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Nurmohamed, 1996 | Nadroparin, 7500 Institute Choay anti-Xa units per day subcutaneously 18-24 hours postoperatively plus compression for 10 days | compression stockings + placebo | Craniotomy or spinal surgery for tumor or injury, 18 years or older, without excess bleeding risk |
| |
| Nadroparin | venous thrombosis, in all type of patients | vs acenocoumarol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 1.13 [0.43 2.97] | p=1.00 | 0 | 360 | 2 | Lopaciuk, Lopez-Beret, | | VTE during follow-up after active anticoagulant treatment | 1.16 [0.35 3.84] | p=1.00 | 0 | 345 | 2 | Lopaciuk, Lopez-Beret, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Lopaciuk, 1999 | LMWH, 85 UI/kg bid followed by Nadroparin 85 IU/kg qd | LMWH, 85 UI/kg bid followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Lopez-Beret, 2001 | LMWH, 1,025 IU/10 kg bid followed by Nadroparin 1,025 IU/10 kg bid | LMWH, 1,025 IU/10 kg bid followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by compression ultrasonography |
| |
| Nadroparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.58 [0.24 1.43] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | Thrombus extension | 0.57 [0.30 1.09] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | All cause death | 0.58 [0.24 1.45] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | Short term haemorrhage | 0.85 [0.24 3.01] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Collaborative European Multicentre, 1991 | Nadroparin Subcutaneous twice daily for 10 Days, 90 U/kg BID | unfractionated heparin intravenous APPTx1.5-2 | | | Prandoni et al , 1992 | Nadroparin Subcutaneous twice daily for >=0 Days, 90 U/kg BID | unfractionated heparin intravenous APPTx1.5-2 | | | Lopaciuk et al , 1992 | Nadroparin Subcutaneous twice daily for 10 Days, 92 U/kg BID | unfractionated heparin subcutaneous twice daily APPTx1.5-2.5 | |
| |
| Nadroparin | | vs twice daily nadroparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.57 [0.29 1.15] | p=1.00 | 0 | 651 | 1 | Charbonnier, | | All cause death | 0.73 [0.31 1.74] | p=1.00 | 0 | 651 | 1 | Charbonnier, | | Bleeding | 0.62 [0.28 1.38] | p=1.00 | 0 | 651 | 1 | Charbonnier, |
| Trial | Studied treatment | Control | Patients |
|---|
| Charbonnier, 1998 | Once daily nadroparin 20,500 (AXa IU/ml)continued for at least 5 days | twice daily
nadroparin 10,250 (AXa IU/ml)continued for at least 5 days | patients with acute symptomatic proximal DVT in popliteal vein or above
documented by venography |
| |
| Reviparin | thrombosis prevention, in general surgery | vs unfractionated heparin | wound haematoma / infection by 44% suggested Bleeding by 31% suggested Major bleeding by 69% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.34 [0.03 3.25] | p=1.00 | 0 | 1351 | 1 | Kakkar, | | asymptomatic DVT | 1.10 [0.65 1.86] | p=1.00 | 0 | 1311 | 1 | Kakkar, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 0.56 [0.35 0.90] | p=0.04 | 0 | 1351 | 1 | Kakkar, | | transfusion | no data | | All cause death | 0.61 [0.14 2.55] | p=1.00 | 0 | 1351 | 1 | Kakkar, | | Bleeding | 0.69 [0.48 1.00] | p=0.04 | 0 | 1351 | 1 | Kakkar, | | Major bleeding | 0.31 [0.10 0.96] | p=0.04 | 0 | 1351 | 1 | Kakkar, |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar, 1993 | Reviparin 1750 anti Xa units | UFH 10 000 units | General and gynaecological surgery |
| |
| Tinzaparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Lassen, 1991 | tinzaparin 50/kg x1 +elastic stockings | Placebo+elastic stockings | Elective hip |
| |
| Tinzaparin | thrombosis prevention, in general surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.35 [0.01 8.87] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | asymptomatic DVT | 0.35 [0.09 1.41] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 1.05 [0.02 54.31] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | transfusion | no data | | Bleeding | 5.26 [0.24 113.14] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Major bleeding | 3.15 [0.12 79.84] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | All cause death | 0.21 [0.01 4.53] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergqvist [42], | Tinzaparin 3500 anti-Xa units | Placebo | |
| |
| Tinzaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.25 [0.24 6.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | asymptomatic DVT | 1.64 [0.70 3.85] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | 1.11 [0.50 2.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Bleeding | no data | | Major bleeding | 0.78 [0.40 1.55] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, |
| Trial | Studied treatment | Control | Patients |
|---|
| Leizorovicz, 1991 | Tinzaparin 2500 and 3500 anti Xa units | UFH 10 000 units | Abdominothoracic and gynaecological surgery |
| |
| Tinzaparin | venous thrombosis, in all type of patients | vs acenocoumarol | recurrent DVT by 79% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.47 [0.17 1.29] | p=1.00 | 0 | 241 | 1 | Romera, | | puylmonary embolism | 1.37 [0.30 6.24] | p=1.00 | 0 | 241 | 1 | Romera, | | recurrent DVT | 0.21 [0.04 0.96] | p=0.04 | 0 | 241 | 1 | Romera, | | VTE during active anticoagulant treatment | 0.73 [0.23 2.37] | p=1.00 | 0 | 241 | 1 | Romera, | | VTE during follow-up after active anticoagulant treatment | 0.17 [0.02 1.44] | p=1.00 | 0 | 241 | 1 | Romera, | | Bleeding | 0.34 [0.04 3.33] | p=1.00 | 0 | 241 | 1 | Romera, |
| Trial | Studied treatment | Control | Patients |
|---|
| Romera, 2009 | tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months | acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) | patients with symptomatic proximal DVT of the lowerlimbs confirmed by compression duplex ultrasound scan |
| |
| Tinzaparin | | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.76 [0.39 1.48] | p=1.00 | 0 | 737 | 1 | Hull, | | VTE during follow-up after active anticoagulant treatment | 1.00 [0.48 2.08] | p=1.00 | 0 | 688 | 1 | Hull, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Hull, 2002 | LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd | UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Tinzaparin | | vs unfractionated heparin | Short term haemorrhage by 91% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.41 [0.16 1.08] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Thrombus extension | no data | | All cause death | 0.49 [0.22 1.07] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Short term haemorrhage | 0.09 [0.01 0.73] | p=0.04 | 0 | 432 | 1 | Hull et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Hull et al , 1992 | Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID | unfractionated heparin intravenous APPTx2-3 | |
| |
| Logiparin | venous thrombosis, in all type of patients | vs twice daily logiparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, | | All cause death | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, | | Bleeding | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, |
| Trial | Studied treatment | Control | Patients |
|---|
| Siegbahn, 1989 | Once daily logiparin 150 XaI U/kgp, imag | twice daily logiparin 75 XaI U/kg | patients with a venographically confirmed episode of DVT |
| |
| UFH | thrombosis prevention, in neurosurgery | vs no treatment | asymptomatic DVT by 82% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Cerrato, | | asymptomatic DVT | 0.18 [0.05 0.65] | p=0.04 | 0 | 100 | 1 | Cerrato, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Cerrato, | | Major bleeding | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Cerrato, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Cerrato, 1978 | Unfractionated heparin, 5000 IU subcutaneously 3 times a day, starting 2 hours preoperatively for +7 days | no treatment | Elective neurosurgery for tumors, 40 years or older |
| |
